Ratings Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 12/06/2025 pm IST			5-day change	1st Jan Change
1,484.00 ^DKK	-0.03%		+2.66%	-0.57%

09/06	Genmab A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08:00 AM
09/06	AlphaValue/Baader Europe Keeps Genmab at Buy, Boosts Price Target on Pipeline Strength	MT

Summary: Genmab A/S

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Highlights: Genmab A/S

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 46% by 2027.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The group usually releases upbeat results with huge surprise rates.

Weaknesses: Genmab A/S

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings Chart: Genmab A/S

Source: Surperformance

ESG chart: Genmab A/S

Source: MSCI

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	GENMAB A/S				1.41TCr
	REGENERON PHARMACEUTICALS, INC.				5.48TCr
	ARGENX SE				3.55TCr
	BEONE MEDICINES LTD.				3.34TCr
	WUXI APPTEC CO., LTD.				2.6TCr
	WUXI BIOLOGICS (CAYMAN) INC.				1.38TCr
	EXELIXIS, INC.				1.13TCr
	Average				2.7TCr
	Weighted average by Cap.

See all sector ratings

Investor (Composite)

Trader (Composite)

ESG MSCI

Financials

Revenue growth

EPS growth

Capital Efficiency (Composite)

Net Margin

Financial Health (Composite)

Valuation

P/E

EV/Revenue

EV/EBITDA

PBR

Dividend Yield

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (4 months)

Analysts' target price evolution (1 year)

Business Predictability

Surprise rates

Analysts' coverage

Analysts' recommendations divergence

Analysts' Target price divergence

Financial estimates divergence

ESG

ESG: Environment

ESG: Social

ESG: Governance

ESG: Controversy

ESG: Ethical controversies

ESG: Human rights controversies

ESG: Tax subsidies controversies

ESG: Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes